[VIEW] agent=Credit Risk Modeling Lead | scenario_id=23 | rounds=20

--- Round 0 ---
[R0.1] Credit Risk Modeling Lead (speak, public): Let's start by reviewing our Q2 2026 CECL allowance for credit losses (ACL). Our model-implied ACL is $126.4M, representing a QoQ change of +$8.1M. I'd like to discuss the drivers behind this movement and any emerging risk signals from the portfolio.
[R0.2] Commercial Portfolio Manager (speak, public): The commercial portfolio is showing some stress signals. Our watchlist has grown by $95M this quarter to $612M, and we've seen a 9% median decline in CRE appraisals. These factors are likely contributing to the increase in model-implied ACL.
[R0.3] Finance Controller (speak, public): The $8.1M QoQ increase in model-implied ACL is material, but still below our disclosure threshold of $10M. Before we finalize, I'd like to understand if there are any specific portfolio segments or risk factors driving this increase. Also, have we considered the potential capital impact given our current CET1 ratio is 10.6%?

--- Round 1 ---
[R1.1] Credit Risk Modeling Lead (speak, public): The increase in model-implied ACL is driven by multiple factors, including the commercial watchlist growth and declining CRE appraisals you mentioned. Our backtesting shows a mean absolute error of 0.42%, which is within acceptable limits. However, we do have two key risk indicators currently breaching their thresholds, which adds to the reserve pressure. I'd like to understand from Finance Controller if the CET1 ratio of 10.6% is constraining our ability to absorb this $8.1M increase, and whether there are any capital planning considerations we should factor into our final ACL recommendation.
[R1.2] Commercial Portfolio Manager (speak, public): I agree that the watchlist growth and declining CRE appraisals are key drivers. Additionally, we're expecting $22M in net charge-offs next quarter, with three large deals exceeding $5M each. This could further pressure our ACL. I'd like to understand from Credit Risk Modeling Lead how these factors are being captured in the model assumptions and if there are any qualitative adjustments being considered to address potential underestimation.
[R1.3] Finance Controller (speak, public): The CET1 ratio of 10.6% is relatively tight given our internal guardrails. An $8.1M ACL increase consumes about 6.75 basis points of CET1. While it's not immediately constraining, we should be mindful of the capital impact, especially if we expect further provisioning pressure from the anticipated $22M in net charge-offs next quarter. Have we considered whether an overlay is needed to address potential model underestimation given these emerging risks?

--- Round 2 ---
[R2.1] Credit Risk Modeling Lead (speak, public): To address the emerging risks and potential underestimation, I'd like to discuss whether we should consider qualitative adjustments or overlays. Our model uses a 12-quarter reversion to long-run loss rates and has a Base 70%/Adverse 30% scenario weighting. Given the Commercial Portfolio Manager's insights on watchlist growth and expected net charge-offs, we should assess if our current approach adequately captures these risks. Finance Controller, can you help quantify the potential capital impact if we were to implement an overlay?
[R2.2] Commercial Portfolio Manager (speak, public): To better understand the potential need for an overlay, can you clarify how our current scenario weightings and reversion methodology are capturing the heightened risk environment? For instance, are there any sensitivity analyses we can run to test the impact of more extreme scenario weightings or faster reversion to long-run loss rates?
[R2.3] Finance Controller (speak, public): To assess the potential need for an overlay, let's examine our current ACL sensitivity to CET1. For every $12M increase in ACL, CET1 is impacted by 10 basis points. An overlay would further consume capital, so we need to carefully weigh the benefits against the capital impact. I'd like to understand from Credit Risk Modeling Lead what the potential range for an overlay might be based on the emerging risks we've discussed.

--- Round 3 ---
[R3.1] Credit Risk Modeling Lead (speak, public): To assess the potential overlay, let's examine our model's sensitivity to different scenario weightings and reversion speeds. If we adjust our Adverse scenario weight from 30% to 50%, the model-implied ACL increases by $4.2M. Additionally, if we accelerate our reversion to 8 quarters instead of 12, it further increases ACL by $2.5M. These adjustments could help capture the heightened risk environment. Finance Controller, can you help quantify the capital impact of these potential adjustments?
[R3.2] Commercial Portfolio Manager (speak, public): To better understand the implications of adjusting our scenario weightings and reversion speeds, can you help me understand how these changes might affect our commercial portfolio's risk profile, particularly in light of our recent watchlist growth and expected net charge-offs?
[R3.3] Finance Controller (speak, public): To quantify the capital impact, an increase of $4.2M from adjusting the Adverse scenario weight and $2.5M from accelerating reversion totals $6.7M. Using our ACL sensitivity to CET1, this would consume about 5.58 basis points of CET1. While not drastic, it's still a meaningful capital impact. We should also consider the disclosure implications - with the total ACL increase now potentially exceeding $10M, we would need to prepare for expanded footnote disclosure. Let's discuss whether these adjustments are sufficient to address the emerging risks or if further overlay considerations are needed.

--- Round 4 ---
[R4.1] Credit Risk Modeling Lead (speak, public): To finalize our Q2 2026 CECL allowance recommendation, let's summarize our key findings and decisions. We've identified significant emerging risks in the commercial portfolio, including watchlist growth and declining CRE appraisals. Our model sensitivity analysis shows that adjusting the Adverse scenario weight to 50% and accelerating reversion to 8 quarters could increase ACL by $6.7M, bringing the total QoQ change to $14.8M. Finance Controller, can you confirm if this level of ACL increase is acceptable from a capital and disclosure perspective?
[R4.2] Commercial Portfolio Manager (speak, public): I agree that the proposed adjustments to the Adverse scenario weight and reversion speed are reasonable given the emerging risks. However, I'd like to highlight that our recent office underwriting tightening, effective April 15, 2026, with a new office CRE LTV cap of 60%, should also be considered when assessing our overall risk profile and potential future ACL needs. Additionally, we should ensure that our disclosure narrative accurately reflects these changes and their impact on our commercial portfolio.
[R4.3] Finance Controller (speak, public): The proposed adjustments to our model, including increasing the Adverse scenario weight to 50% and accelerating reversion to 8 quarters, result in a total ACL increase of $14.8M, which exceeds our $10M disclosure threshold. We'll need to prepare an expanded footnote disclosure. From a capital perspective, this $14.8M increase consumes about 12.33 basis points of CET1, bringing our ratio to approximately 10.467%. While manageable, we should monitor this closely. I recommend we finalize our Q2 2026 CECL allowance at $141.2M and prepare the necessary disclosures. Let's also ensure our overlay documentation is prepared, as we've used multiple risk drivers to justify our approach.

--- Round 5 ---
[R5.1] Credit Risk Modeling Lead (speak, public): I agree with finalizing our Q2 2026 CECL allowance at $141.2M. To ensure we are audit-ready, let's confirm that our documentation includes the rationale for the Adverse scenario weight adjustment and reversion speed acceleration, as well as the impact of the office underwriting tightening on our risk profile. Finance Controller, can you lead the preparation of the expanded footnote disclosure, and Commercial Portfolio Manager, can you help document the portfolio risk insights and any relevant qualitative adjustments? Let's also schedule a follow-up to review our ACL position against actual charge-offs and watchlist developments in the next quarter.
[R5.2] Commercial Portfolio Manager (speak, public): I agree with finalizing our Q2 2026 CECL allowance at $141.2M. I'll work on documenting the portfolio risk insights, including the impact of the office underwriting tightening and other relevant qualitative adjustments. I'll also ensure that our documentation is aligned with the rationale for the Adverse scenario weight adjustment and reversion speed acceleration. Let's proceed with preparing the necessary disclosures and schedule a follow-up to review our ACL position against actual charge-offs and watchlist developments in the next quarter.
[R5.3] Finance Controller (speak, public): I recommend we finalize the Q2 2026 CECL allowance at $141.2M and prepare the necessary disclosures. Let's ensure our documentation is thorough and aligned with the rationale for our model adjustments and portfolio insights.

--- Round 6 ---
[R6.1] Credit Risk Modeling Lead (speak, public): I believe we've reached a consensus on finalizing our Q2 2026 CECL allowance at $141.2M. Let's ensure that all necessary documentation is completed and disclosures are prepared accordingly. I'll work on compiling the rationale for our model adjustments and ensuring audit readiness. Let's schedule a follow-up meeting to review our ACL position against actual charge-offs and watchlist developments in the next quarter.
[R6.2] Commercial Portfolio Manager (leave, public): 
[R6.3] Finance Controller (speak, public): I agree that we've reached a consensus on finalizing our Q2 2026 CECL allowance at $141.2M. Let's ensure that all necessary documentation is completed and disclosures are prepared accordingly. I'll work on preparing the expanded footnote disclosure and ensuring that our overlay documentation is thorough and aligned with our rationale for model adjustments and portfolio insights. Let's schedule a follow-up meeting to review our ACL position against actual charge-offs and watchlist developments in the next quarter.

--- Round 7 ---
[R7.1] Credit Risk Modeling Lead (speak, public): I believe we've reached a consensus on finalizing our Q2 2026 CECL allowance at $141.2M. Let's ensure that all necessary documentation is completed and disclosures are prepared accordingly. I'll work on compiling the rationale for our model adjustments and ensuring audit readiness. Finance Controller, please confirm once the expanded footnote disclosure is prepared, and let's schedule that follow-up meeting to review our ACL position against actual charge-offs and watchlist developments in the next quarter.
[R7.2] Commercial Portfolio Manager (leave, public): 
[R7.3] Finance Controller (speak, public): I've prepared the expanded footnote disclosure and ensured that our overlay documentation is thorough and aligned with our rationale for model adjustments and portfolio insights. I recommend we proceed with finalizing our Q2 2026 CECL allowance at $141.2M and schedule a follow-up meeting to review our ACL position against actual charge-offs and watchlist developments in the next quarter.

--- Round 8 ---
[R8.1] Credit Risk Modeling Lead (speak, public): I believe we've completed all necessary steps to finalize our Q2 2026 CECL allowance at $141.2M. Let's confirm that all documentation is in order and schedule that follow-up meeting. Finance Controller, please share the final disclosure documents once ready.
[R8.2] Commercial Portfolio Manager (leave, public): 
[R8.3] Finance Controller (leave, public): 

--- Round 9 ---
[R9.1] Credit Risk Modeling Lead (leave, public): 
[R9.2] Commercial Portfolio Manager (leave, public): 
[R9.3] Finance Controller (leave, public): 

--- Round 10 ---
[R10.1] Credit Risk Modeling Lead (leave, public): 
[R10.2] Commercial Portfolio Manager (leave, public): 
[R10.3] Finance Controller (leave, public): 

--- Round 11 ---
[R11.1] Credit Risk Modeling Lead (leave, public): 
[R11.2] Commercial Portfolio Manager (leave, public): 
[R11.3] Finance Controller (leave, public): 

--- Round 12 ---
[R12.1] Credit Risk Modeling Lead (leave, public): 
[R12.2] Commercial Portfolio Manager (leave, public): 
[R12.3] Finance Controller (leave, public): 

--- Round 13 ---
[R13.1] Credit Risk Modeling Lead (leave, public): 
[R13.2] Commercial Portfolio Manager (leave, public): 
[R13.3] Finance Controller (leave, public): 

--- Round 14 ---
[R14.1] Credit Risk Modeling Lead (leave, public): 
[R14.2] Commercial Portfolio Manager (leave, public): 
[R14.3] Finance Controller (leave, public): 

--- Round 15 ---
[R15.1] Credit Risk Modeling Lead (leave, public): 
[R15.2] Commercial Portfolio Manager (leave, public): 
[R15.3] Finance Controller (leave, public): 

--- Round 16 ---
[R16.1] Credit Risk Modeling Lead (leave, public): 
[R16.2] Commercial Portfolio Manager (leave, public): 
[R16.3] Finance Controller (leave, public): 

--- Round 17 ---
[R17.1] Credit Risk Modeling Lead (leave, public): 
[R17.2] Commercial Portfolio Manager (leave, public): 
[R17.3] Finance Controller (leave, public): 

--- Round 18 ---
[R18.1] Credit Risk Modeling Lead (leave, public): 
[R18.2] Commercial Portfolio Manager (leave, public): 
[R18.3] Finance Controller (leave, public): 

--- Round 19 ---
[R19.1] Credit Risk Modeling Lead (leave, public): 
[R19.2] Commercial Portfolio Manager (leave, public): 
[R19.3] Finance Controller (leave, public): 

